Daniel Capitán

PhD student at Laura Soucek’s lab. Vall d’Hebron Institute of Oncology (VHIO). “La Caixa” Foundation INPhINIT fellow.

[Vall d’Hebron Institute of Oncology (VHIO) @VHIO]

#AACR26 | Elena Garralda, Andrea García Garijo, Íñigo González-Larreategui y Daniel Capitán-Leo presentaron diversos estudios y pósteres sobre inmunoterapia y medicina de precisión en el @AACR, uno de los congresos líderes en investigación del cáncer.

➡️ https://t.co/DMxRCHhk7m
#UITM

[PEPTOMYC @peptomyc]

Excited to share that @dcapi14 is presenting today (April 20) at #AACR2026 exciting work on #MYC inhibition (#OMO-103) in KRAS-driven cancers. (Poster 1880). Work from @VHIO, @icreacommunity & @peptomyc !

[LSoucekLab @LSoucekLab]

We are proud to announce that our PhD student, @dcapi14, presented yesterday a poster at #EACR2025 in Lisbon titled “MYC targeting by Omomyc boosts efficacy and overcomes resistance to KRAS inhibitors”. Well done, Dani! @VHIO @EACRnews #cancer

[Becas Fundación "la Caixa" @BecariosFLC]

1/🎓🧬¿Cómo explicarías qué es la inmunología a una persona de 5, 15 o 50 años?

Hoy, en el #DíaMundialdelaInmunología, los #becariosFundlaCaixa Ana Victoria Lechuga (@avlecvie), Daniel Capitán (@dcapi14) y June Ereño (@JuneErenoOrbea) aceptan el reto.👇

▶️¡Dale al play y descúbrelo!

[Beques Fundació ”la Caixa” @BecarisFLC]

1/ 🎓🧬 Com explicaries què és la immunologia a una persona de 5, 15 o 50 anys?

Avui, en el #DiaMundialDeLaImmunologia, els #becarisFundlaCaixa Ana Victoria Lechuga (@avlecvie), Daniel Capitán (@dcapi14) i June Ereño (@JuneErenoOrbea) accepten el repte.👇

▶️Dona-li al play!

[Vall d’Hebron Institute of Oncology (VHIO) @VHIO]

👏 Enhorabona @dcapi14 i Cristina Molina ‼️

Dos investigadors del VHIO han estat guardonats amb beques #INPhINIT @FundlaCaixa per dur a terme el seu doctorat i avançar en la recerca en càncer 👉 https://t.co/RimQlwFVX4

[LSoucekLab @LSoucekLab]

Congratulations to our @dcapi14 for being awarded a @FundlaCaixa PhD fellowship! We are all proud of you 👏

[Vall d’Hebron Institute of Oncology (VHIO) @VHIO]

🚀 Today, the Induction session for VHIO's first-year PhD students took place. More training sessions coming up in the next days! 

#VHIOAcademy

[Vall d’Hebron Institute of Oncology (VHIO) @VHIO]

🔴 El fàrmac OMO-103, desenvolupat per @peptomyc, es provarà com a teràpia per a pacients amb osteosarcoma avançat.

🔬 L'assaig està finançat per l'@OSInstitute i té com a objectius avaluar l'activitat clínica, la seguretat i la farmacodinàmica ➡️ https://t.co/mnARCBAVtq

#OSTEOMYC

[LSoucekLab @LSoucekLab]

Today our @ignigor presented at the XVIII congress of the Catalan Society of Immunology talking about the therapeutic impact and reactivation of tumor immunity by MYC inhibition in KRAS-driven NSCLC with diverse mutational landscapes. 👏 @VHIO @peptomyc

[Daniel Capitán @dcapi14]

@IsabelFabregat @idibell_cat @UniBarcelona @ICO_oncologia @ASEICAnews Really nice to see you Isabel! And congrats for your award 🙌

[LSoucekLab @LSoucekLab]

@dcapi14 is presenting today a poster titled “Myc targeting by Omomyc enhances the efficacy and overcomes resistance to the KRAS inhibitor sotorasib in NSCLC” at #ASEICAcongress. 👏 @VHIO @peptomyc

[PEPTOMYC @peptomyc]

@SilviaCasacub is representing @Peptomyc and the @LSoucekLab (at @VHIO) at #ASEICACongress with a talk and poster about how MYC inhibition reprograms tumor immunity and enhances immunotherapy efficacy in KRASmut NSCLC. 👏

[Vall d’Hebron Institute of Oncology (VHIO) @VHIO]

Congrats on the INPhINIT Fellowship! 🎉 Exciting journey ahead at VHIO‼️

[Daniel Capitán @dcapi14]

I am thrilled to share that I have been awarded the prestigious "La Caixa" Foundation INPhINIT Retaning Fellowship @BecarisFLC , which will suport my PhD Studies at @VHIO over the next four years. Very grateful to @LauraSoucek, @SilviaCasacub, @ignigor and the whole @LSoucekLab!

[Daniel Capitán @dcapi14]

@nogales_pons @CNIOStopCancer La millooooor! 🙌

[Daniel Capitán @dcapi14]

Very proud of the team!! 👏

[Laura Soucek @LauraSoucek]

I am happy to share our review in Signal Transduction and Targeted Therapy (@Nature) on #RAS and #MYC cooperation, co-authored by @SilviaCasacub, @ignigor, and @dcapi14. RAS and MYC are two of the most commonly altered oncogenes in cancer. https://t.co/7lD3HkNN1k

[PEPTOMYC @peptomyc]

Our review in Signal Transduction and Targeted Therapy (@Nature) on #RAS and #MYC cooperation, co-authored by @SilviaCasacub, @ignigor, @dcapi14 and @LauraSoucek is out. RAS and MYC are two of the most commonly altered oncogenes in cancer. https://t.co/Uq44kUt9Pw

[Vall d’Hebron Institute of Oncology (VHIO) @VHIO]

🔬 Los resultados del primer ensayo clínico de #Omomyc en humanos han llevado a la puesta en marcha de un segundo ensayo clínico fase Ib en pacientes con cáncer de páncreas metastásico. 

➡️ https://t.co/sAr1QZmNZu

#AGAUR #NextGeneration | @LauraSoucek @ElenaGarralda

[Vall d'Hebron @vallhebron]

The 2nd #PhDdayVH with @VHIR_ and @VHIO is about to begin! We'll enjoy a day full of activities to empower the PhD community in #VallHebron and share their research projects.

With the support of Sarstedt, @thermofisher, @VectorBuilder, @BestoursCorp, @AstraZenecaES

Follow this thread to keep up to date 👇